Brief: Crescent Biopharma Announces First Patient Dosed In Ascend Phase 1/2 Clinical Trial Of CR-001
18/02/2026 13:57
Feb 18 (Reuters) - Crescent Biopharma Inc CBIO.O: CRESCENT BIOPHARMA ANNOUNCES FIRST PATIENT DOSED IN ASCEND PHASE 1/2 CLINICAL TRIAL OF CR-001 FOR THE TREATMENT OF ADVANCED SOLID TUMORS CRESCENT BIOPHARMA INC: ASCEND IS FIRST OF FOUR CLINICAL TRIALS ACROSS PORTFOLIO EXPECTED TO INITIATE IN 2026 CRESCENT BIOPHARMA INC: ANTICIPATES REPORTING PROOF-OF-CONCEPT DATA IN Q1 OF 2027 Source text: ID:nGNX8wgWFd Further company coverage: CBIO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Crescent Biopharma
See all newsBrief: Crescent Biopharma - Potential To Initiate First CR-001 Phase 3 Study In Early 2028
Brief: Crescent Biopharma Announces FDA Clearance Of Ind Application For CR-002, A Pd-L1-Targeted Topoisomerase Inhibitor Adc, For The Treatment Of Solid Tumors
Crescent Biopharma posts smaller-than-expected Q2 net loss
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Crescent Biopharma slips on $125 mln share offering